Diabetes Clinical Trials in San Jose
View 102 new treatments for Diabetes in San Jose, CA, and nearby areas, such as Fremont, Hayward, San Mateo, Santa Clara and Sunnyvale. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
INV 202 for Diabetic Kidney Disease
Inversago Clinic, Salinas + 2 more
This trial tests a new drug called INV-202 in adults with Diabetic Kidney Disease caused by Type 1 or Type 2 diabetes. The goal is to see if the drug is effective, safe, and well-tolerated, and how it behaves in the body.Show More
Verified
Recruiting
Phase 2
Est. 6 - 12 Weeks
Glenn Crater, MD
Study Director
Coffee for Type 2 Diabetes
Research Clinic, Berkeley + 2 more
Coffee has been found to have beneficial effects on cognitive function and blood sugar control. Benefits include reduced risk of cognitive decline and improved performance on cognitive tests, as well as reduced risk of diabetes and improved blood sugar control in people with diabetes, a population that is at a higher risk of cognitive decline. These effects have been observed for both caffeinated and decaffeinated coffee, and have been associated with the polyphenol chlorogenic acid (CGA). This polyphenol has been found to be more bioavailable in certain coffees, known as "speciality coffee" as defined by the Specialty Coffee Association of America, depending on agriculture, roasting, and brewing method. This current project will bring together these previous findings to explore the effects of specialty coffee on cognitive function and glycaemic control in people with type 2 diabetes through a randomized control trial with two groups: a high CGA specialty coffee group and a conventional coffee control group. Participants will be quasi-randomly assigned to one of these two groups following the completion of a 4-week run-in period during which participants will consume conventional coffee only. The length of the experimental arms is 8 weeks, therefore the total length of the study is 12 weeks. At the beginning and the end of each experimental arm participants will undertake a cognitive assessment online using the Gorilla platform, and a series of questionnaires relating to health and mood measures (details in procedure). Cognitive function will also be assessed at the beginning of the 4-week run-in period.Show More
Verified
Recruiting
No Placebo Trial
N/A
Est. 3 - 12 Weeks
Daniel Lamport, PhD
Principal Investigator
Ertugliflozin for Cardiovascular Disease
Research Clinic, Stanford + 1 more
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.Show More
Waitlist
No Placebo Trial
Phase < 1
Est. 5 - 8 Weeks
Tracey McLaughlin, MD
Principal Investigator
High-Dose Metformin for Type 2 Diabetes
Research Clinic, San Francisco + 3 more
The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).
Recruiting
No Placebo Trial
Phase < 1
Est. 3 - 6 Weeks
Shylaja Srinivasan, MD
Principal Investigator
Extended Insulin Bolus for Type 1 Diabetes
Research Clinic, San Francisco + 1 more
This study aims to evaluate whether the use of an extended bolus will improve glucose control with high-fat high protein meals using a closed-loop system. The new knowledge gained from this study may provide a method to allow for the proper administration of insulin over an extended period to mitigate the risk of prolonged hyperglycemia or early hypoglycemia.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Laya Ekhlaspour, MD
Principal Investigator
Metformin for Prediabetes
Research Clinic, Palo Alto + 1 more
This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Gregory G. Schwartz, PhD MD
Study Chair
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Eli Lilly Clinic, Burlingame + 1 more
This trial is testing a new medication called tirzepatide for people with type 2 diabetes. Tirzepatide helps control blood sugar by making the body produce more insulin and reducing appetite. The study aims to see if switching to this new treatment is more effective than current therapies.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Pioglitazone or Tirzepatide for Type 2 Diabetes
Research Clinic, Stanford + 1 more
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD) and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Teplizumab for Pediatric Type 1 Diabetes
Provention Bio Clinic, San Francisco + 2 more
This trial tests the safety of teplizumab, an IV medication, in children under 8 with early signs of type 1 diabetes. The drug aims to protect insulin-producing cells from immune system attacks and has shown potential in delaying the onset of type 1 diabetes.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 4 - 6 Weeks
Provention Bio, Inc., MD
Study Director
GLP-1A + Metformin + Mediterranean Diet for Prediabetes
Research Clinic, Stanford + 1 more
The study team will invite participants with prediabetes or mild diabetes (HbA1c 5.7-7.0) to join a 5-year research study that will define subphenotypes of type 2 diabetes based on underlying physiology (eg insulin resistance, beta-cell dysfunction, incretin defect, liver insulin resistance) and then test the hypothesis that response to three first-line treatments will vary according to metabolic subphenotype. Variables of interest include glucose, cardiovascular risk markers, and weight. Treatments include Mediterranean diet, metformin, and a GLP-1 agonist. Participants will go through an initial screening, followed by three treatment periods, each lasting 4 months with 3 month washout in-between treatment periods. This study will help us understand how personalized treatments can help control blood glucose, reduce cardiovascular risk, and manage weight. While there may be minor side effects-like slight discomfort from blood tests, gastrointestinal symptoms from some of the medications, and small radiation exposure from DXA body scans-the treatments offered in this study have all been well studied and are known to lower risk for diabetes and cardiovascular diseaseShow More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Tracey McLaughlin, MD
Principal Investigator
Page 1 of 13
Frequently Asked Questions
Explore related conditions